Dr. Martin Langer

• Born 1965
• Biochemist and molecular biologist
• Studied biology at the Technical University of Darmstadt, at Adelaide University, Australia, and at University of Karlsruhe
• Doctoral thesis on enzymes with rare prosthetic groups and their catalytic behavior (University of Karlsruhe)

Martin Langer at BRAIN Biotech

• 1995: Project leader
• 1999 – 2005: Worked for the BRAIN Biotech spin-off company VISCUM (pharmaceutical biotechnology)
  • Business development management
  • Identification of external cooperation partners
  • Acquisition and use of venture capital
  • Member of the VISCUM supervisory board (1999 – 2003)
• 2005: Head of Corporate Development Unit at BRAIN
  • With CEO jointly responsible for corporate development
  • Realization and coordination of the strategic alliance “NatLifE 2020”
• 2013: Appointment to the Executive Board of BRAIN Biotech AG
• 2015: Head of the IPO team at BRAIN (successful IPO at Deutsche Börse Frankfurt in February 2016)
• 2018 – 2020: Responsibility for business unit Industrial BioSolutions
• 2020: Head of Business Development
  • Responsibility for New Business Development and TMS business of BRAIN Biotech AG

• 2023: Managing Director BioScience Operations Zwingenberg

Martin is also a member of the German section of the Pharma Licensing Club. Apart form that he has represented BRAIN since June 2018 as deputy chairman of the executive board in the IWBio e.V. German Industrial Biotechnology Association. In July 2020 he was appointed as a member of the supervisory board of Enzymicals AG in Greifswald, Germany.

“The application of biotechnology opens up the opportunity for us as a society to biologize entire industries and thus make them more sustainable. Being actively involved in this fills me with pride!”

Contact me via business@brain-biotech.com
or feel free to contact me via LinkedIn.